title: TLR2 may influence the behavior of the malignant clone in B-CLL.
abstract: B-cell receptor (BCR) and Toll-like receptor (TLR) stimulation and integration with signals from the pathogen or immune cells and their products determine the B-cell antibody response. Low expression of BCR is the hallmark of B lymphocytes in CLL, however little is known about the expression and function of TLR in B-CLL. We studied TLR2, TLR4, IL-6 and mIL-6Rα expression on mRNA and protein level in CD19(+) subpopulation of normal lymphocytes and the CD19(+)CD5(+) subpopulation from B-CLL. Experiments were performed on unstimulated and stimulated lymphocytes [Staphylococcus aureus Cowan I (SAC) and lipopolysaccharide (LPS) from Escherichia coli - TLR2- and TLR4-specific agonists, respectively]. We showed undetectable or low IL-6 expression, which seems to be specific for B-CLL lymphocytes. Induction of TLR4 mRNA upon LPS stimulation affected the expression of IL-6, but not of mIL-6Rα. Increased expression of TLR2 (MFI) after LPS and SAC stimulation did not correlate with mIL-6Rα receptor expression. B-CLL CD19(+)CD5(+) lymphocytes showed a significant increase in TLR2 expression at the protein level after stimulation with SAC and LPS compared to normal CD19(+) lymphocytes. TLR2 may influence the behaviour of the malignant clone in B-CLL.
authors.affiliation: Department of Clinical Genetics, Medical University of Lublin, Lublin, Poland. hagenetyka@wp.pl
authors.forename: Halina
authors.initials: H
authors.lastname: Antosz
authors.forename: Joanna
authors.initials: J
authors.lastname: Sajewicz
authors.forename: Barbara
authors.initials: B
authors.lastname: Marzec-Kotarska
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszyńska
authors.forename: Jacek
authors.initials: J
authors.lastname: Baszak
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Jargiełło-Baszak
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D015850:Interleukin-6 / Q000096:biosynthesis / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011947:Receptors, Antigen, B-Cell / Q000096:biosynthesis / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000096:biosynthesis / Q000276:immunology*; D051197:Toll-Like Receptor 4 / Q000096:biosynthesis / Q000276:immunology
chemical_list: C508600:IL6 protein, human; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011947:Receptors, Antigen, B-Cell; C495342:TLR2 protein, human; C495345:TLR4 protein, human; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4